-
Application of RNA origami technology in synthetic biology
Time of Update: 2022-10-12
Molecular models show that dCas9 binds to the guide RNA-RNA origami fusion molecule, bringing transcription factors into the promoter sequence.
Molecular models show that dCas9 binds to the guide RNA-RNA origami fusion molecule, bringing transcription factors into the promoter sequence.
-
Pharmaceutical companies continue to lay out the ADC market, and an innovation war is inevitable
Time of Update: 2022-09-14
Huadong Pharmaceutical said that by carrying out equity investment and product cooperation with Heidelberg Pharma, an emerging technology company in the field of ADC, and introducing a number of ADC innovative products, the company will further enrich the pipeline of innovative products in the field of oncology and achieve a differentiated in-depth layout in the field of ADC.
-
Nature: Why is the mRNA vaccine developed for the original strain effective against Omicron when used as a booster
Time of Update: 2022-06-08
The study showed that a third dose of the mRNA vaccine developed for the original new coronavirus (SARS-CoV-2) strain enhanced the immune system's ability to produce broadly neutralizing antibodies, including the ability to produce broadly neutralizing antibodies, compared with just two doses.
-
JAMA sub-journal: Maintenance IVIG is associated with significantly less recurrence of MOG-AD disease
Time of Update: 2022-05-22
Recent studies suggest that maintenance intravenous immunoglobulin (IVIG) may be an effective treatment for preventing recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ; Few studies have evaluated IVIG in adult patients .
-
TJBio announces that its bispecific antibody TJ-CD4B has been approved for Phase 1 clinical trials in China
Time of Update: 2021-12-27
On December 16, 2021, Horizon Biotech announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has officially approved the bispecific antibody TJ-CD4B (also known as ABL111) for the treatment of solid tumors (including gastric cancer, Phase 1 clinical study of esophageal-gastric junction adenocarcinoma, esophageal adenocarcinoma and pancreatic duct adenocarcinoma .
-
National Health Commission: Our national defense control strategy is still effective against Omi Keron mutant
Time of Update: 2021-12-01
The Institute of Viral Diseases of the Chinese Center for Disease Control and Prevention has established a specific nucleic acid detection method for the Omi Keron mutant strain, and continues to carry out viral genome monitoring for possible imported cases .
-
New progress Quanxin Biologics QX002N injection for new indications obtained implied permission from clinical trials
Time of Update: 2021-11-04
Lupus nephritis (LN) refers to a disease in which systemic lupus erythematosus (SLE) is associated with different pathological types of immune damage in both kidneys and accompanied by clinical manifestations of obvious kidney damage .
-
New research from Nature confirms that mRNA vaccines are effective against 16 mutated new coronaviruses including Delta
Time of Update: 2021-10-21
The Yale University research team tested blood samples from vaccinators and confirmed that two existing mRNA vaccines can enhance the immune system’s response to infection and prevent more than a dozen new coronavirus variants, including the delta variant .
-
After Aducanumab was approved, the development of new drugs for Alzheimer's disease is surging
Time of Update: 2021-08-16
Text | Pickup BayOn June 7, the FDA accelerated the approval of Biogen/Eisai’s Aβ (amyloid β) antibody Aduhelm (aducanumab) for the treatment of Alzheimer’s disease (AD) patients with a biological product license (BLA) based on the biomarker surrogate endpoint.
-
Cell's important finding: The presence of type I natural antibodies similar to 2G12 antibodies in the human body may become a new target for HIV-1 vaccines
Time of Update: 2021-06-22
The author only tested the reactivity of this FDG antibody to recombinant HIV-1 Env and SARS-CoV-2 S proteoglycans, but this may exclude other types of polysaccharide forms in the body .
-
Nature Commun: Hard-core prevention of HIV, is AIDS still an "incurable disease
Time of Update: 2021-06-21
Its research shows that the humanized CCR5 monoclonal antibody Leronlimab can effectively prevent non-primates such as rhesus monkeys from infecting ape/human HIV virus.
In this study, the researchers first evaluated the ability of Leronlimab to inhibit the spread of HIV virus between cells in an in vitro diffusion test.
-
Scientists have developed a new method for detecting autoimmune diseases by ferritin multimeric antigen-antibody
Time of Update: 2021-06-17
In order to improve the diagnostic efficiency of autoimmune diseases, the team of Yan Xiyun, an academician of the Chinese Academy of Sciences and a researcher of the Institute of Biophysics of the Chinese Academy of Sciences, and Li Zhanguo, a professor at Peking University People’s Hospital, developed a new method based on ferritin to display multimeric antigens and multimeric antigens using pSS as a research model.
-
Nat Commun: RNF167 targets the degradation of CASTOR1 and activates mTORC1 to promote tumor development
Time of Update: 2021-03-19
RNF167-mediated ubiquitination and AKT1-mediated phosphorylation promote the occurrence and development of breast cancerBreast cancerFurther studies have shown that several cell types with higher CASTOR1 expression are not sensitive to the regulation of arginine.
-
Inebilizumab Neuroscolonshritis Spectrum Disorder Study Published in The Lancet
Time of Update: 2021-02-15
The results showed that after 28 weeks of treatment, in AQP4-IgG serologically positive patients, the risk of an NMOSD attack was significantly reduced by 77% (HR-0.227, p The study also reached a critical secondary endpoint: inebilizumab significantly reduced disability exacerbation compared to placebo (15.5% vs.
-
Sanofi vaccine is approved by the European Union for the prevention of meningococcal disease in people 12 months and older
Time of Update: 2021-01-07
On 23 November, the European Commission (EC) approved the Sanofi-Pasteur vaccine MenQuadfi® to be actively immunized against invasive meningococcal disease caused by Meningitis A, C, W and Y.
